We narrowed to 41,376 results for: LAT;

#226117

Contains 748 traditional and newly predicted epigenetic regulators using epigenetic network analyses that integrated gene codependency (DepMap) and protein-protein interaction data (BioPlex).

Rui Lu

Zhou et al Blood. 2024 Aug 16:blood.2023023644. doi

Oct. 29, 2024

Academic Institutions and Nonprofits only

#1000000019

A complete set of plasmids, optimized for human expression, to build your own TALE nucleases (TALENs) and transcription factors (TALE-TFs) for genome editing and transcription modulation applications.

Feng Zhang

Dec. 16, 2011

Academic Institutions and Nonprofits only

#135632-AAV1

Ready-to-use AAV1 particles produced from pAAV-S5E2-GCaMP6f (#135632). In addition to the viral particles, you will also receive purified pAAV-S5E2-GCaMP6f plasmid DNA. Expression of GCaMP6f under the control of the E2 regulatory element. These AAV preparations are suitable purity for injection into animals.

Jordane Dimidschstein

Vormstein-Schneider et al Nat Neurosci. 2020 Dec;23(12):1629-1636.

Nov. 11, 2020

Academic Institutions and Nonprofits only

#135632-AAV9

Ready-to-use AAV9 particles produced from pAAV-S5E2-GCaMP6f (#135632). In addition to the viral particles, you will also receive purified pAAV-S5E2-GCaMP6f plasmid DNA. Expression of GCaMP6f under the control of the E2 regulatory element. These AAV preparations are suitable purity for injection into animals.

Jordane Dimidschstein

Vormstein-Schneider et al Nat Neurosci. 2020 Dec;23(12):1629-1636.

Sept. 13, 2021

Academic Institutions and Nonprofits only

#198513-AAV1

Ready-to-use AAV1 particles produced from pAAV_hSyn-PdCO-EGFP-WPRE (#198513). In addition to the viral particles, you will also receive purified pAAV_hSyn-PdCO-EGFP-WPRE plasmid DNA. Synapsin-driven expression of the optimized opsin PdCO in frame with EGFP. These AAV preparations are suitable purity for injection into animals.

Ofer Yizhar

Wietek et al Nat Methods. 2024 May 29. doi: 10.1038/s

April 10, 2024

Academic Institutions and Nonprofits only

#198510-AAV5

Ready-to-use AAV5 particles produced from pAAV_hSyn-PdCO-mScarlet-WPRE (#198510). In addition to the viral particles, you will also receive purified pAAV_hSyn-PdCO-mScarlet-WPRE plasmid DNA. Syn-driven expression of optimized PdCO in frame with mScarlet. These AAV preparations are suitable purity for injection into animals.

Ofer Yizhar

Wietek et al Nat Methods. 2024 May 29. doi: 10.1038/s

Sept. 27, 2024

Academic Institutions and Nonprofits only

#198510-AAV1

Ready-to-use AAV1 particles produced from pAAV_hSyn-PdCO-mScarlet-WPRE (#198510). In addition to the viral particles, you will also receive purified pAAV_hSyn-PdCO-mScarlet-WPRE plasmid DNA. Syn-driven expression of optimized PdCO in frame with mScarlet. These AAV preparations are suitable purity for injection into animals.

Ofer Yizhar

Wietek et al Nat Methods. 2024 May 29. doi: 10.1038/s

Jan. 27, 2025

Academic Institutions and Nonprofits only

#198513-AAV5

Ready-to-use AAV5 particles produced from pAAV_hSyn-PdCO-EGFP-WPRE (#198513). In addition to the viral particles, you will also receive purified pAAV_hSyn-PdCO-EGFP-WPRE plasmid DNA. Synapsin-driven expression of the optimized opsin PdCO in frame with EGFP. These AAV preparations are suitable purity for injection into animals.

Ofer Yizhar

Wietek et al Nat Methods. 2024 May 29. doi: 10.1038/s

April 10, 2024

Academic Institutions and Nonprofits only

#1000000109

A collection of C. elegans plasmids used for building homologous repair templates that incorporate a self-excising drug selection cassette (SEC), based on the SapTrap CRISPR/Cas Toolkit.

Bob Goldstein

June 23, 2017

Academic Institutions and Nonprofits only

#198511-AAV1

Ready-to-use AAV1 particles produced from pAAV_hSyn-DIO-PdCO-mScarlet-WPRE (#198511). In addition to the viral particles, you will also receive purified pAAV_hSyn-DIO-PdCO-mScarlet-WPRE plasmid DNA. Syn-driven Cre-dependent expression of optimized PdCO in frame with mScarlet. These AAV preparations are suitable purity for injection into animals.

Ofer Yizhar

Wietek et al Nat Methods. 2024 May 29. doi: 10.1038/s

Sept. 27, 2024

Academic Institutions and Nonprofits only

#135630-AAV1

Ready-to-use AAV1 particles produced from pAAV-S5E2-dTom-nlsdTom (#135630). In addition to the viral particles, you will also receive purified pAAV-S5E2-dTom-nlsdTom plasmid DNA. Bicistronic expression of dTomato and nuclear-targeted dTomato under the control of the E2 regulatory element. These AAV preparations are suitable purity for injection into animals.

Jordane Dimidschstein

Vormstein-Schneider et al Nat Neurosci. 2020 Dec;23(12):1629-1636.

Jan. 6, 2022

Academic Institutions and Nonprofits only

#135634-AAV9

Ready-to-use AAV9 particles produced from pAAV-S5E2-ChR2-mCherry (#135634). In addition to the viral particles, you will also receive purified pAAV-S5E2-ChR2-mCherry plasmid DNA. Expression of ChR2-mCherry under the control of the E2 regulatory element. These AAV preparations are suitable purity for injection into animals.

Jordane Dimidschstein

Vormstein-Schneider et al Nat Neurosci. 2020 Dec;23(12):1629-1636.

Sept. 15, 2021

Academic Institutions and Nonprofits only

#135635-AAV9

Ready-to-use AAV9 particles produced from pAAV-S5E2-Gq-P2A-dTomato (#135635). In addition to the viral particles, you will also receive purified pAAV-S5E2-Gq-P2A-dTomato plasmid DNA. Expression of Gq-DREADD and dTomato (physically separate) under the control of the E2 regulatory element. These AAV preparations are suitable purity for injection into animals.

Jordane Dimidschstein

Vormstein-Schneider et al Nat Neurosci. 2020 Dec;23(12):1629-1636.

Aug. 27, 2021

Academic Institutions and Nonprofits only

#135631-AAV9

Ready-to-use AAV9 particles produced from pAAV-S5E2-GFP-fGFP (#135631). In addition to the viral particles, you will also receive purified pAAV-S5E2-GFP-fGFP plasmid DNA. Bicistronic expression of GFP and membrane-targeted GFP under the control of the E2 regulatory element. These AAV preparations are suitable purity for injection into animals.

Jordane Dimidschstein

Vormstein-Schneider et al Nat Neurosci. 2020 Dec;23(12):1629-1636.

Sept. 27, 2023

Academic Institutions and Nonprofits only

#198511-AAV5

Ready-to-use AAV5 particles produced from pAAV_hSyn-DIO-PdCO-mScarlet-WPRE (#198511). In addition to the viral particles, you will also receive purified pAAV_hSyn-DIO-PdCO-mScarlet-WPRE plasmid DNA. Syn-driven Cre-dependent expression of optimized PdCO in frame with mScarlet. These AAV preparations are suitable purity for injection into animals.

Ofer Yizhar

Wietek et al Nat Methods. 2024 May 29. doi: 10.1038/s

Sept. 27, 2024

Academic Institutions and Nonprofits only

#135634-AAV1

Ready-to-use AAV1 particles produced from pAAV-S5E2-ChR2-mCherry (#135634). In addition to the viral particles, you will also receive purified pAAV-S5E2-ChR2-mCherry plasmid DNA. Expression of ChR2-mCherry under the control of the E2 regulatory element. These AAV preparations are suitable purity for injection into animals.

Jordane Dimidschstein

Vormstein-Schneider et al Nat Neurosci. 2020 Dec;23(12):1629-1636.

Nov. 29, 2021

Academic Institutions and Nonprofits only

#135632-PHPeB

Ready-to-use AAV PHP.eB particles produced from pAAV-S5E2-GCaMP6f (#135632). In addition to the viral particles, you will also receive purified pAAV-S5E2-GCaMP6f plasmid DNA. Expression of GCaMP6f under the control of the E2 regulatory element. These AAV were produced with the PHPeB serotype, which permits efficient transduction of the central nervous system. These AAV preparations are suitable purity for injection into animals.

Jordane Dimidschstein

Vormstein-Schneider et al Nat Neurosci. 2020 Dec;23(12):1629-1636.

Sept. 13, 2021

Academic Institutions and Nonprofits only

#135630-AAV9

Ready-to-use AAV9 particles produced from pAAV-S5E2-dTom-nlsdTom (#135630). In addition to the viral particles, you will also receive purified pAAV-S5E2-dTom-nlsdTom plasmid DNA. Bicistronic expression of dTomato and nuclear-targeted dTomato under the control of the E2 regulatory element. These AAV preparations are suitable purity for injection into animals.

Jordane Dimidschstein

Vormstein-Schneider et al Nat Neurosci. 2020 Dec;23(12):1629-1636.

Nov. 29, 2021

Academic Institutions and Nonprofits only

#135631-AAV1

Ready-to-use AAV1 particles produced from pAAV-S5E2-GFP-fGFP (#135631). In addition to the viral particles, you will also receive purified pAAV-S5E2-GFP-fGFP plasmid DNA. Bicistronic expression of GFP and membrane-targeted GFP under the control of the E2 regulatory element. These AAV preparations are suitable purity for injection into animals.

Jordane Dimidschstein

Vormstein-Schneider et al Nat Neurosci. 2020 Dec;23(12):1629-1636.

Sept. 15, 2021

Academic Institutions and Nonprofits only

#198516-AAV5

Ready-to-use AAV5 particles produced from pAAV_EF1a-DIO-PdCO-mScarlet-ER-miniWPRE (#198516). In addition to the viral particles, you will also receive purified pAAV_EF1a-DIO-PdCO-mScarlet-ER-miniWPRE plasmid DNA. Ef1a-driven, Cre-dependent expression of the optimized opsin PdCO in frame with mScarlet. These AAV preparations are suitable purity for injection into animals.

Ofer Yizhar

Wietek et al Nat Methods. 2024 May 29. doi: 10.1038/s

April 10, 2024

Academic Institutions and Nonprofits only